Emad A Rakha

List of Publications by Citations

410 papers	20,586 citations	60 h-index	132 g-index
445 ext. papers	24,677 ext. citations	6.1 avg, IF	6.65 L-index

#	Paper	IF	Citations
410	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **2012**, 486, 346-52	50.4	3479
409	Prognostic markers in triple-negative breast cancer. *Cancer*, **2007**, 109, 25-32	6.4	963
408	Basal-like breast cancer: a critical review. *Journal of Clinical Oncology*, **2008**, 26, 2568-81	2.2	657
407	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616
406	Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*, **2010**, 12, 207	8.3	459
405	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. *Modern Pathology*, **2011**, 24, 157-67	9.8	447
404	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. *International Journal of Cancer*, **2005**, 116, 340-50	7.5	443
403	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. *Annals of Oncology*, **2014**, 25, 1536-43	10.3	433
402	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Modern Pathology*, **2018**, 31, 1770-1786	9.8	428
401	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clinical Cancer Research*, **2009**, 15, 2302-10	12.9	371
400	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. *Cancer Research*, **2009**, 69, 3802-9	10.1	340
399	Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. *Journal of Clinical Oncology*, **2008**, 26, 3153-8	2.2	336
398	Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. *Modern Pathology*, **2005**, 18, 1295-304	9.8	257
397	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. *Breast Cancer Research*, **2013**, 15, R92	8.3	248
396	Phyllodes tumours of the breast: a consensus review. *Histopathology*, **2016**, 68, 5-21	7.3	220
395	Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. *Journal of Clinical Oncology*, **2007**, 25, 4772-8	2.2	213
394	Triple-negative/basal-like breast cancer: review. *Pathology*, **2009**, 41, 40-7	1.6	204

393	Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. *Modern Pathology*, **2005**, 18, 26-35	9.8	196
392	Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. *European Journal of Cancer*, **2008**, 44, 73-83	7.5	164
391	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. *European Journal of Cancer*, **2006**, 42, 3149-56	7.5	164
390	Updated UK Recommendations for HER2 assessment in breast cancer. *Journal of Clinical Pathology*, **2015**, 68, 93-9	3.9	155
389	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. *Breast Cancer Research and Treatment*, **2010**, 119, 283-93	4.4	155
388	Combinatorial biomarker expression in breast cancer. *Breast Cancer Research and Treatment*, **2010**, 120, 293-308	4.4	150
387	The prognostic significance of lymphovascular invasion in invasive breast carcinoma. *Cancer*, **2012**, 118, 3670-80	6.4	145
386	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. *Histopathology*, **2007**, 50, 434-8	7.3	132
385	E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. *Histopathology*, **2005**, 46, 685-93	7.3	132
384	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *British Journal of Cancer*, **2012**, 107, 800-7	8.7	130
383	Tubular carcinoma of the breast: further evidence to support its excellent prognosis. *Journal of Clinical Oncology*, **2010**, 28, 99-104	2.2	129
382	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. *British Journal of Cancer*, **2008**, 99, 327-34	8.7	122
381	Expression of BRCA1 protein in breast cancer and its prognostic significance. *Human Pathology*, **2008**, 39, 857-65	3.7	115
380	Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. *Histopathology*, **2008**, 53, 650-7	7.3	113
379	Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *American Journal of Surgical Pathology*, **2010**, 34, 1472-9	6.7	110
378	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. *American Journal of Surgical Pathology*, **2013**, 37, e1-11	6.7	109
377	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, **2017**, 19, 58	8.3	100
376	Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. *Breast Cancer Research and Treatment*, **2008**, 111, 121-7	4.4	96

375	Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. *American Journal of Surgical Pathology*, **2011**, 35, 1093-103	6.7	95
374	Lobular breast carcinoma and its variants. *Seminars in Diagnostic Pathology*, **2010**, 27, 49-61	4.3	95
373	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. *Breast Cancer Research*, **2012**, 14, R3	8.3	94
372	A case-controlled study of the oncologic safety of fat grafting. *Plastic and Reconstructive Surgery*, **2015**, 135, 1263-1275	2.7	87
371	Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. *Apoptosis: an International Journal on Programmed Cell Death*, **2017**, 22, 357-368	5.4	85
370	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. *Modern Pathology*, **2011**, 24, 774-85	9.8	84
369	Are triple-negative tumours and basal-like breast cancer synonymous?. *Breast Cancer Research*, **2007**, 9, 404; author reply 405	8.3	83
368	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. *Nature Communications*, **2018**, 9, 1816	17.4	82
367	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast Cancer Research and Treatment*, **2011**, 127, 591-9	4.4	82
366	Metastatic triple-negative breast cancer. *Clinical Oncology*, **2011**, 23, 587-600	2.8	81
365	A CD44?/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 979-95	4.4	79
364	The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. *American Journal of Pathology*, **2017**, 187, 2139-2151	5.8	78
363	Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. *European Journal of Cancer*, **2008**, 44, 1541-51	7.5	74
362	Targeting XRCC1 deficiency in breast cancer for personalized therapy. *Cancer Research*, **2013**, 73, 1621-34	10.1	71
361	Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. *International Journal of Cancer*, **2011**, 129, 1417-24	7.5	70
360	Loss of Dicer expression is associated with breast cancer progression and recurrence. *Breast Cancer Research and Treatment*, **2012**, 135, 403-13	4.4	69
359	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. *Breast Cancer Research and Treatment*, **2009**, 117, 199-204	4.4	69
358	Chromosome 16 tumor-suppressor genes in breast cancer. *Genes Chromosomes and Cancer*, **2006**, 45, 527-35	5	69

357	Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. *British Journal of Cancer*, **2014**, 110, 1688-97	8.7	68
356	Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. *British Journal of Cancer*, **2015**, 112, 283-9	8.7	67
355	Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-sampling Raman micro-spectroscopy. *Physics in Medicine and Biology*, **2014**, 59, 6141-52	3.8	67
354	The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2010**, 120, 603-12	4.4	66
353	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. *British Journal of Cancer*, **2016**, 114, 917-28	8.7	64
352	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. *Breast Cancer Research and Treatment*, **2010**, 122, 45-53	4.4	63
351	Patho-biological aspects of basal-like breast cancer. *Breast Cancer Research and Treatment*, **2009**, 113, 411-22	4.4	61
350	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. *Nature Communications*, **2018**, 9, 3533	17.4	60
349	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 335-46	4.4	59
348	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. *Breast Cancer Research and Treatment*, **2016**, 159, 215-27	4.4	59
347	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 11-21	4.4	59
346	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. *Breast Cancer Research*, **2018**, 20, 21	8.3	58
345	Basal-like breast carcinoma: from expression profiling to routine practice. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 860-8	5	58
344	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. *Molecular Oncology*, **2015**, 9, 569-85	7.9	57
343	The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. *Diagnostic Cytopathology*, **2010**, 38, 874-9	1.4	57
342	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. *Molecular Oncology*, **2015**, 9, 204-17	7.9	55
341	Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 768-776	9.7	55
340	The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. *Histopathology*, **2014**, 64, 609-15	7.3	55

339	Molecular classification of breast cancer: what the pathologist needs to know. *Pathology*, **2017**, 49, 111-119	1.9	54
338	Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. *Breast Cancer Research*, **2018**, 20, 69	8.3	54
337	Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. *Advances in Anatomic Pathology*, **2011**, 18, 255-67	5.1	53
336	Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. *American Journal of Surgical Pathology*, **2012**, 36, 1683-90	6.7	52
335	Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. *Histopathology*, **2011**, 58, 626-32	7.3	49
334	The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. *Breast Cancer Research and Treatment*, **2008**, 110, 427-37	4.4	49
333	Biological and clinical significance of PARP1 protein expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 149, 353-62	4.4	48
332	Sonographic correlations with the new molecular classification of invasive breast cancer. *European Radiology*, **2009**, 19, 2342-8	8	48
331	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5929-5938	12.9	47
330	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. *Breast Cancer Research and Treatment*, **2010**, 120, 83-93	4.4	47
329	MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. *British Journal of Cancer*, **2018**, 118, 258-265	8.7	47
328	Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 301-10	4.4	46
327	IL6/STAT3 Signaling Hijacks Estrogen Receptor Enhancers to Drive Breast Cancer Metastasis. *Cancer Cell*, **2020**, 38, 412-423.e9	24.3	46
326	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. *Pathobiology*, **2018**, 85, 23-34	3.6	45
325	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 407-16	4.4	45
324	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. *Breast Cancer Research and Treatment*, **2014**, 145, 339-48	4.4	44
323	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. *British Journal of Cancer*, **2015**, 112, 1929-37	8.7	43
322	Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. *Modern Pathology*, **2010**, 23, 1357-63	9.8	43

321	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. *Breast Cancer Research and Treatment*, **2010**, 121, 41-51	4.4	43
320	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. *Journal of Pathology*, **2015**, 237, 166-78	9.4	42
319	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. *Breast Cancer Research*, **2015**, 17, 59	8.3	42
318	Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. *Breast Cancer Research and Treatment*, **2009**, 113, 59-66	4.4	42
317	A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. *Computers in Biology and Medicine*, **2010**, 40, 318-30	7	42
316	Are triple-negative and basal-like breast cancer synonymous?. *Clinical Cancer Research*, **2008**, 14, 618; author reply 618-9	12.9	42
315	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. *Journal of Pathology*, **2016**, 238, 677-88	9.4	42
314	Artificial intelligence in digital breast pathology: Techniques and applications. *Breast*, **2020**, 49, 267-273	3.6	41
313	An approach to the diagnosis of spindle cell lesions of the breast. *Histopathology*, **2016**, 68, 33-44	7.3	41
312	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. *Cancer Immunology Research*, **2017**, 5, 292-299	12.5	40
311	IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. *Cancer Immunology, Immunotherapy*, **2018**, 67, 537-549	7.4	40
310	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. *Modern Pathology*, **2018**, 31, 1226-1236	9.8	40
309	Immunoprofile of metaplastic carcinomas of the breast. *Histopathology*, **2017**, 70, 975-985	7.3	39
308	Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. *Oncotarget*, **2014**, 5, 12936-49	3.3	39
307	The role of glutaminase in cancer. *Histopathology*, **2020**, 76, 498-508	7.3	39
306	C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. *Cancer*, **2014**, 120, 163-71	6.4	38
305	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. *Breast Cancer Research and Treatment*, **2012**, 135, 555-69	4.4	38
304	The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. *Breast Cancer Research and Treatment*, **2009**, 114, 243-50	4.4	38

303	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. *Histopathology*, **2018**, 73, 887-896	7.3	38
302	Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. *Histopathology*, **2013**, 62, 894-8	7.3	37
301	Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. *Pathobiology* , **2015**, 82, 113-23	3.6	37
300	Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. *Breast Cancer Research*, **2009**, 11, R90	8.3	37
299	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. *Histopathology*, **2017**, 71, 258-268	7.3	36
298	DNA damage repair in breast cancer and its therapeutic implications. *Pathology*, **2017**, 49, 156-165	1.6	36
297	High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. *Histopathology*, **2015**, 66, 740-6	7.3	36
296	Breast carcinoma with basal phenotype: mammographic findings. *American Journal of Roentgenology*, **2008**, 191, 346-51	5.4	36
295	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. *Molecular Oncology*, **2015**, 9, 115-27	7.9	35
294	Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. *Journal of Pathology*, **2011**, 224, 434-7	9.4	35
293	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. *Journal of Clinical Pathology*, **2010**, 63, 790-5	3.9	35
292	Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) - an alternative to surgery in selected cases. *Breast*, **2008**, 17, 546-9	3.6	35
291	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. *British Journal of Cancer*, **2013**, 109, 1886-94	8.7	34
290	The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 140, 307-16	4.4	34
289	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. *Modern Pathology* , **2017**, 30, 69-84	9.8	34
288	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. *Breast*, **2013**, 22, 13-8	3.6	34
287	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. *Journal of Clinical Pathology*, **2011**, 64, 995-1000	3.9	34
286	The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. *International Journal of Cancer*, **2007**, 120, 1311-7	7.5	34

285	Expression profiling technology: its contribution to our understanding of breast cancer. *Histopathology*, **2008**, 52, 67-81	7.3	34
284	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. *Breast Cancer Research and Treatment*, **2017**, 164, 341-348	4.4	33
283	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. *BMC Cancer*, **2014**, 14, 908	4.8	33
282	Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. *Modern Pathology*, **2013**, 26, 496-501	9.8	33
281	RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2011**, 128, 315-26	4.4	33
280	Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. *Journal of Clinical Pathology*, **2012**, 65, 710-4	3.9	33
279	Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. *Journal of Pathology*, **2004**, 203, 754-61	9.4	33
278	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 387-399	4.4	33
277	Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. *Histopathology*, **2018**, 72, 183-190	7.3	33
276	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1057-65	6.1	32
275	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. *Histopathology*, **2010**, 57, 212-9	7.3	32
274	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. *Breast Cancer Research and Treatment*, **2015**, 150, 81-90	4.4	30
273	Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. *Neoplasia*, **2014**, 16, 982-91	6.4	30
272	RECQL4 helicase has oncogenic potential in sporadic breast cancers. *Journal of Pathology*, **2016**, 238, 495-501	9.4	29
271	Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. *International Journal of Cancer*, **2010**, 126, 1761-9	7.5	29
270	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. *Histopathology*, **2016**, 68, 45-56	7.3	29
269	Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. *Journal of Clinical Pathology*, **2017**, 70, 51-57	3.9	28
268	Metadherin: A Therapeutic Target in Multiple Cancers. *Frontiers in Oncology*, **2019**, 9, 349	5.3	28

267	Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. *British Journal of Cancer*, **2015**, 112, 901-11	8.7	28
266	National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1301-2	2.2	28
265	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. *Journal of Clinical Pathology*, **2021**, 74, 443-447	3.9	28
264	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. *Histopathology*, **2018**, 73, 339-344	7.3	28
263	Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. *British Journal of Cancer*, **2015**, 112, 1613-5	8.7	28
262	Characteristics of basal cytokeratin expression in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 23-37	4.4	28
261	Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. *European Journal of Cancer*, **2008**, 44, 2580-6	7.5	28
260	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. *British Journal of Cancer*, **2004**, 91, 1591-6	8.7	28
259	The pioneer factor PBX1 is a novel driver of metastatic progression in ER□positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
258	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. *Breast Cancer Research and Treatment*, **2016**, 159, 41-53	4.4	28
257	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. *Molecular Oncology*, **2016**, 10, 213-23	7.9	26
256	SUMOylation proteins in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 144, 519-30	4.4	26
255	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 33-44	4.4	26
254	Pitfalls in outcome prediction of breast cancer. *Journal of Clinical Pathology*, **2013**, 66, 458-64	3.9	26
253	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. *Carcinogenesis*, **2016**, 37, 63-71	4.6	25
252	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. *Histopathology*, **2015**, 67, 529-37	7.3	25
251	Impact of basal-like breast carcinoma determination for a more specific therapy. *Pathobiology*, **2008**, 75, 95-103	3.6	25
250	Diagnostic challenges in papillary lesions of the breast. *Pathology*, **2018**, 50, 100-110	1.6	25

249	Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. *Oncotarget*, **2018**, 9, 25946-25956	3.3	25
248	Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. *Clinical Cancer Research*, **2018**, 24, 4566-4578	12.9	24
247	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. *Journal of Pathology: Clinical Research*, **2016**, 2, 32-40	5.3	24
246	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. *British Journal of Cancer*, **2018**, 118, 1115-1122	8.7	23
245	Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. *Histopathology*, **2013**, 62, 695-701	7.3	23
244	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. *Journal of Clinical Pathology*, **2020**, 73, 76-82	3.9	23
243	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 468, 493-502	5.1	22
242	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. *Breast Cancer Research and Treatment*, **2016**, 156, 9-20	4.4	22
241	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. *Breast Cancer Research*, **2019**, 21, 83	8.3	22
240	The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. *Clinical Radiology*, **2008**, 63, 1228-35	2.9	22
239	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. *Histopathology*, **2015**, 67, 279-93	7.3	21
238	Breast cancer intratumour heterogeneity: current status and clinical implications. *Histopathology*, **2018**, 73, 717-731	7.3	21
237	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. *Modern Pathology*, **2018**, 31, 1807-1815	9.8	21
236	Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. *Breast Cancer Research*, **2018**, 20, 39	8.3	21
235	Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens. *Histopathology*, **2011**, 59, 543-8	7.3	21
234	Topo2β protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. *British Journal of Cancer*, **2010**, 103, 1794-800	8.7	21
233	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. *Journal of Medical Screening*, **2007**, 14, 210-4	1.4	21
232	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. *Breast*, **2017**, 35, 151-156	3.6	21

231	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. *Modern Pathology*, **2020**, 33, 1056-1064	9.8	21
230	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. *Histopathology*, **2016**, 68, 1030-9	7.3	21
229	Prolyl-4-hydroxylase subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). *British Journal of Cancer*, **2018**, 119, 1518-1526	8.7	21
228	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. *Breast Cancer Research and Treatment*, **2015**, 151, 325-33	4.4	20
227	Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. *Cancer Research*, **2018**, 78, 2524-2535	10.1	20
226	Breast cancer histologic grading using digital microscopy: concordance and outcome association. *Journal of Clinical Pathology*, **2018**, 71, 680-686	3.9	20
225	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. *Breast Cancer Research and Treatment*, **2012**, 136, 419-27	4.4	20
224	Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 519-29	4.4	20
223	EpCAM expression is an indicator of recurrence in basal-like breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 575-82	4.4	20
222	Connexin 43 is an independent predictor of patient outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2019**, 174, 93-102	4.4	20
221	Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. *Frontiers in Oncology*, **2016**, 6, 145	5.3	19
220	Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. *Histopathology*, **2017**, 70, 622-631	7.3	18
219	Phenotypic characterisation of breast cancer: the role of CDC42. *Breast Cancer Research and Treatment*, **2017**, 164, 317-325	4.4	18
218	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. *Artificial Intelligence in Medicine*, **2019**, 97, 27-37	7.4	18
217	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. *Histopathology*, **2012**, 60, 854-63	7.3	18
216	The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. *Diagnostic Cytopathology*, **2011**, 39, 81-6	1.4	18
215	High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. *International Journal of Cancer*, **2005**, 114, 720-9	7.5	18
214	The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. *International Journal of Cancer*, **2020**, 146, 2296-2304	7.5	18

213	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Induces Synthetic Lethality and Chemoprevention. *Cancer Research*, **2018**, 78, 6818-6827	10.1	18
212	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. *Breast Cancer Research and Treatment*, **2019**, 178, 535-544	4.4	17
211	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 511-22	4.4	17
210	The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 139-53	4.4	17
209	Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). *European Journal of Cancer*, **2009**, 45, 1162-1167	7.5	17
208	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. *Oncotarget*, **2015**, 6, 21964-78	5.2	17
207	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. *Breast Cancer Research and Treatment*, **2016**, 157, 65-75	4.4	17
206	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. *Modern Pathology*, **2019**, 32, 967-976	9.8	17
205	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. *Breast Cancer Research and Treatment*, **2016**, 159, 457-67	4.4	16
204	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. *Breast Cancer Research and Treatment*, **2012**, 134, 171-80	4.4	16
203	Papillary carcinoma of the breast: diagnostic agreement and management implications. *Histopathology*, **2016**, 69, 862-870	7.3	16
202	Glutamate dehydrogenase (GLUD1) expression in breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 79-91	4.4	16
201	Assessment of and rearrangements in breast adenomyoepitheliomas. *Npj Breast Cancer*, **2019**, 5, 6	7.8	15
200	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. *British Journal of Cancer*, **2019**, 120, 1075-1082	8.7	15
199	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. *British Journal of Cancer*, **2020**, 122, 1496-1506	8.7	15
198	Impact of breast cancer grade discordance on prediction of outcome. *Histopathology*, **2018**, 73, 904-915	7.3	15
197	Lack of expression of the proteins GMPR2 and PPAR□are associated with the basal phenotype and patient outcome in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 137, 127-37	4.4	15
196	The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 175, 27-38	4.4	14

195	Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. *British Journal of Radiology*, **2016**, 89, 20140644	3.4	14
194	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. *Breast Cancer Research and Treatment*, **2014**, 144, 273-85	4.4	14
193	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. *Histopathology*, **2017**, 70, 632-642	7.3	14
192	Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. *BMC Cancer*, **2014**, 14, 995	4.8	14
191	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 349-357	4.4	14
190	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 1460-1472	9.8	13
189	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. *Gynecologic Oncology*, **2019**, 153, 416-424	4.9	13
188	A novel prognostic two-gene signature for triple negative breast cancer. *Modern Pathology*, **2020**, 33, 2208-2220	9.8	13
187	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. *Npj Breast Cancer*, **2020**, 6, 9	7.8	13
186	Clinical utility of reverse phase protein array for molecular classification of breast cancer. *Breast Cancer Research and Treatment*, **2016**, 155, 25-35	4.4	13
185	ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. *Breast Cancer Research and Treatment*, **2014**, 147, 25-37	4.4	13
184	Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 721-31	4.4	13
183	Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. *Journal of Clinical Oncology*, **2012**, 30, 2929-30; author reply 2931	2.2	13
182	PIK3C□expression by fibroblasts promotes triple-negative breast cancer progression. *Journal of Clinical Investigation*, **2020**, 130, 3188-3204	15.9	13
181	Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. *Histopathology*, **2020**, 76, 865-874	7.3	13
180	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. *British Journal of Cancer*, **2020**, 122, 94-101	8.7	13
179	Current and future applications of artificial intelligence in pathology: a clinical perspective. *Journal of Clinical Pathology*, **2021**, 74, 409-414	3.9	13
178	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. *Cancer Letters*, **2020**, 469, 124-133	9.9	13

177	New Advances in Molecular Breast Cancer Pathology. *Seminars in Cancer Biology*, **2021**, 72, 102-113	12.7	13
176	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. *British Journal of Cancer*, **2021**, 124, 494-505	8.7	13
175	Invasion in breast lesions: the role of the epithelial-stroma barrier. *Histopathology*, **2018**, 72, 1075-1083	7.3	13
174	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. *Scientific Reports*, **2017**, 7, 43984	4.9	12
173	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. *British Journal of Cancer*, **2019**, 120, 1129-1136	8.7	12
172	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. *Journal of Pathology*, **2019**, 248, 326-338	9.4	12
171	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. *Npj Breast Cancer*, **2020**, 6, 20	7.8	12
170	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
169	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. *Histopathology*, **2018**, 73, 545-558	7.3	12
168	BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 3681-3691	12.9	12
167	Construction of tissue microarrays from core needle biopsies - a systematic literature review. *Histopathology*, **2016**, 68, 323-32	7.3	12
166	The role of PIP5K1 pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 inhibitor. *Oncogene*, **2019**, 38, 375-389	9.2	12
165	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 239-250	6.1	12
164	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. *Breast Cancer Research and Treatment*, **2020**, 182, 267-282	4.4	12
163	Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 173, 93-102	4.4	12
162	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. *Modern Pathology*, **2021**, 34, 1271-1281	8.8	12
161	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. *Histopathology*, **2019**, 74, 1025-1035	7.3	11
160	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. *Scientific Reports*, **2020**, 10, 3009	4.9	11

159	Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. *Histopathology*, **2017**, 70, 681-692	7.3	11
158	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. *ISRN Oncology*, **2013**, 2013, 675051		11
157	Influence of E-cadherin expression on the mammographic appearance of invasive nonlobular breast carcinoma detected at screening. *Radiology*, **2009**, 253, 51-5	20.5	11
156	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. *Breast Cancer Research*, **2020**, 22, 85	8.3	11
155	Pleomorphic adenoma-like tumour of the breast. *Histopathology*, **2016**, 68, 405-10	7.3	11
154	The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 293-305	4.4	11
153	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. *Breast Cancer Research and Treatment*, **2015**, 150, 91-103	4.4	10
152	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. *European Journal of Cancer*, **2015**, 51, 1897-903	7.5	10
151	The prognostic significance of ALDH1A1 expression in early invasive breast cancer. *Histopathology*, **2020**, 77, 437-448	7.3	10
150	Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. *Breast Cancer Research and Treatment*, **2018**, 169, 277-286	4.4	10
149	Invasive Lobular Carcinoma Mimicking Papillary Carcinoma: A Report of Three Cases. *Pathobiology*, **2016**, 83, 221-7	3.6	10
148	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. *Breast Cancer Research and Treatment*, **2014**, 146, 309-20	4.4	10
147	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 317-30	4.4	10
146	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. *British Journal of Cancer*, **2017**, 117, 1176-1184	8.7	10
145	Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes. *Cytopathology*, **2010**, 21, 27-34	1.3	10
144	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). *Modern Pathology*, **2008**, 21, 1060-1; author reply 1061-2	9.8	10
143	Adenomyoepithelioma of the breast: a proposal for classification. *Histopathology*, **2021**, 79, 465-479	7.3	10
142	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. *Breast Cancer Research and Treatment*, **2016**, 158, 287-95	4.4	10

141	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. *Breast Cancer Research and Treatment*, **2018**, 170, 525-533	4.4	9
140	High nuclear MSK1 is associated with longer survival in breast cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 509-517	4.9	9
139	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. *Histopathology*, **2019**, 75, 931-937	7.3	9
138	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85Deficient Cancer Cells and Influence Platinum Sensitivity. *Cells*, **2019**, 8,	7.9	9
137	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. *Histopathology*, **2017**, 70, 456-465	7.3	9
136	PIASexpression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. *Journal of Clinical Pathology*, **2014**, 67, 301-6	3.9	9
135	The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. *Histopathology*, **2009**, 54, 419-27	7.3	9
134	The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. *Journal of Clinical Pathology*, **2012**, 65, 624-30	3.9	9
133	FKBPL: a marker of good prognosis in breast cancer. *Oncotarget*, **2015**, 6, 12209-23	3.3	9
132	Digital pathology for primary diagnosis of screen-detected breast lesionsexperimental data, validation and experience from four centres. *Histopathology*, **2020**, 76, 968-975	7.3	9
131	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 639-649	9.8	9
130	Feasibility of integrated high-wavenumber Raman imaging and fingerprint Raman spectroscopy for fast margin assessment in breast cancer surgery. *Journal of Raman Spectroscopy*, **2020**, 51, 1986-1995	2.3	8
129	Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. *Pathobiology*, **2020**, 87, 218-231	3.6	8
128	Diagnostic concordance of reporting lymphovascular invasion in breast cancer. *Journal of Clinical Pathology*, **2018**, 71, 802-805	3.9	8
127	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. *Molecular Diagnosis and Therapy*, **2018**, 22, 79-90	4.5	8
126	The low nuclear grade breast neoplasia family. *Diagnostic Histopathology*, **2012**, 18, 124-132	0.7	8
125	Evaluation of touch preparation cytology during frozen-section diagnoses of pulmonary lesions. *Journal of Clinical Pathology*, **2010**, 63, 675-7	3.9	8
124	Infiltrative epitheliosis of the breast. *Journal of Clinical Pathology*, **2012**, 65, 766-8	3.9	8

123	The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. *Journal of Clinical Pathology*, **2012**, 65, 1097-9	3.9	8
122	The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. *British Journal of Cancer*, **2020**, 123, 1543-1552	8.7	8
121	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 79-90	4.4	8
120	Morphogenesis of the papillary lesions of the breast: phenotypic observation. *Journal of Clinical Pathology*, **2016**, 69, 64-9	3.9	7
119	Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. *Placenta*, **2017**, 56, 79-85	3.4	7
118	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. *British Journal of Cancer*, **2019**, 121, 776-785	8.7	7
117	ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. *Breast Cancer Research*, **2016**, 18, 113	8.3	7
116	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. *Modern Pathology*, **2018**, 31, 1675-1682	9.8	7
115	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. *British Journal of Cancer*, **2017**, 117, 826-834	8.7	7
114	Prognostic significance of nucleolar assessment in invasive breast cancer. *Histopathology*, **2020**, 76, 671-684	7.3	7
113	Determining breast cancer biomarker status and associated morphological features using deep learning. *Communications Medicine*, **2021**, 1,		7
112	Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers. *Breast Cancer Research and Treatment*, **2019**, 175, 105-115	4.4	7
111	The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. *PLoS ONE*, **2018**, 13, e0207593	3.7	7
110	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. *Modern Pathology*, **2019**, 32, 1473-1485	9.8	6
109	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 541-551	4.4	6
108	Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. *Histopathology*, **2020**, 77, 303-313	7.3	6
107	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. *British Journal of Cancer*, **2018**, 118, 1142-1151	8.7	6
106	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. *Cancers*, **2019**, 11,	6.6	6

105	Screen-detected malignant breast lesions diagnosed following benign (B2) or normal (B1) needle core biopsy diagnoses. *European Journal of Cancer*, **2010**, 46, 1835-40	7.5	6
104	Gigantic recurrent abdominal desmoid tumour: a case report. *Hernia: the Journal of Hernias and Abdominal Wall Surgery*, **2007**, 11, 193-7	3.2	6
103	Are triple negative tumours and basal-like breast cancer synonymous?. *Breast Cancer Research*, **2007**, 9, R80	8.3	6
102	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. *Cancers*, **2021**, 13,	6.6	6
101	Spindle cell lesions of the breast: a diagnostic approach. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1	5.1	6
100	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. *Histopathology* , **2016**, 69, 20-4	7.3	6
99	Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity?. *Pathobiology*, **2019**, 86, 83-91	3.6	6
98	Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 615-627	4.4	6
97	Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. *Journal of Pathology: Clinical Research*, **2017**, 3, 105-114	5.3	5
96	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. *BMC Cancer*, **2020**, 20, 425	4.8	5
95	The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. *Breast Cancer Research and Treatment*, **2020**, 182, 581-589	4.4	5
94	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 557-564	4.4	5
93	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. *Cancers*, **2021**, 13,	6.6	5
92	Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. *Scientific Reports*, **2019**, 9, 16987	4.9	5
91	Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study. *Journal of Clinical Pathology*, **2019**, 72, 800-804	3.9	5
90	Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. *Malaysian Journal of Pathology*, **2014**, 36, 3-17	1.7	5
89	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 176, 63-73	4.4	4
88	Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 6263-6271	5.6	4

87	Visual histological assessment of morphological features reflects the underlying molecular profile in invasive breast cancer: a morphomolecular study. *Histopathology*, **2020**, 77, 631-645	7.3	4
86	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma. *Clinical Cancer Research*, **2020**, 26, 2898-2907	12.9	4
85	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. *Breast Cancer Research and Treatment*, **2018**, 172, 61-68	4.4	4
84	Integrating breast cancer genetics into clinical practice. *Womens Health*, **2012**, 8, 99-112	3	4
83	The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. *Oncotarget*, **2018**, 9, 29508-29524	3.3	4
82	Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. *Modern Pathology*, **2021**, 34, 1780-1794	9.8	4
81	The intra-tumoural stroma in patients with breast cancer increases with age. *Breast Cancer Research and Treatment*, **2020**, 179, 37-45	4.4	4
80	Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. *Cancer and Metastasis Reviews*, **2021**, 40, 319-339	9.6	4
79	Combined total internal reflection AF spectral-imaging and Raman spectroscopy for fast assessment of surgical margins during breast cancer surgery. *Biomedical Optics Express*, **2021**, 12, 940-954	3.5	4
78	Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives. *Journal of Global Oncology*, **2018**, 4, 1-20	2.6	4
77	Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. *Pathology Research and Practice*, **2017**, 213, 27-33	3.4	3
76	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. *Cancers*, **2020**, 12,	6.6	3
75	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 1-12	4.4	3
74	Eighth Edition Cancer Staging Manual of Breast Cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool?. *Journal of Clinical Pathology*, **2018**, 71, 1028-1029	3.9	3
73	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. *Breast Journal*, **2019**, 25, 1143-1153	1.2	3
72	Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast. *Histopathology*, **2012**, 60, 1166-7	7.3	3
71	Efficacy of an incident-reporting system in cellular pathology: a practical experience. *Journal of Clinical Pathology*, **2012**, 65, 643-8	3.9	3
70	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920974201	5.4	3

69	RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers.. *Molecular Biomedicine*, **2020**, 1, 19	3.1	3
68	The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. *Cancers*, **2020**, 13,	6.6	3
67	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. *British Journal of Cancer*, **2020**, 123, 1513-1520	8.7	3
66	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. *Breast Cancer Research*, **2021**, 23, 42	8.3	3
65	Werner Syndrome Protein Expression in Breast Cancer. *Clinical Breast Cancer*, **2021**, 21, 57-73.e7	3	3
64	Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. *Frontiers in Oncology*, **2020**, 10, 593211	5.3	3
63	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. *Histopathology*, **2021**, 78, 759-771	7.3	3
62	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. *BMC Cancer*, **2018**, 18, 1027	4.8	3
61	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. *Cancers*, **2021**, 13,	6.6	3
60	Predicting the Economic Impact of the COVID-19 Pandemic in the United Kingdom Using Time-Series Mining. *Economies*, **2021**, 9, 137	2	3
59	Machine learning-based prediction of breast cancer growth rate in vivo. *British Journal of Cancer*, **2019**, 121, 497-504	8.7	2
58	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. *Pathobiology*, **2015**, 82, 172-8	3.6	2
57	Phyllodes Tumor of the Breast **2012**, 243-256		2
56	Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance. *Histopathology*, **2021**, 80, 515	7.3	2
55	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio .0, HER2 copy number . *British Journal of Cancer*, **2021**, 124, 1836-1842	8.7	2
54	Molecular disruption of DNA polymerase for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. *Oncogene*, **2021**, 40, 2496-2508	9.2	2
53	Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision. *Histopathology*, **2021**, 79, 187-199	7.3	2
52	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. *British Journal of Cancer*, **2019**, 120, 728-745	8.7	2

51	Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers. *Biomedicines*, **2021**, 9,	4.8	2
50	Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. *Histopathology*, **2021**, 78, 871-881	7.3	2
49	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.. *Scientific Reports*, **2022**, 12, 2742	4.9	2
48	Standardization of the tumor-stroma ratio scoring method for breast cancer research.. *Breast Cancer Research and Treatment*, **2022**, 193, 545	4.4	2
47	Molecular Pathology of Precancerous Lesions of the Breast. *Molecular Pathology Library*, **2015**, 51-62		1
46	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. *Molecular Pathology Library*, **2015**, 177-195		1
45	Molecular Pathology of Breast Cancer Metastasis. *Molecular Pathology Library*, **2015**, 271-289		1
44	Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.. *Breast Cancer Research and Treatment*, **2022**, 192, 529	4.4	1
43	Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. *Npj Breast Cancer*, **2021**, 7, 143	7.8	1
42	Grading of Invasive Carcinoma **2017**, 87-95		1
41	Papillary Carcinomas **2017**, 137-152		1
40	PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 5015-5024	5.6	1
39	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 317-331	4.4	1
38	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. *Theranostics*, **2021**, 11, 8350-8361	12.1	1
37	Artificial Intelligence for Advance Requesting of Immunohistochemistry in Diagnostically Uncertain Prostate Biopsies		1
36	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 621-630	4.4	1
35	Visual assessment of mitotic figures in breast cancer: a comparative study between light microscopy and whole slide images. *Histopathology*, **2021**, 79, 913-925	7.3	1
34	Digital Technology in Diagnostic Breast Pathology and Immunohistochemistry.. *Pathobiology*, **2021**, 1-9	3.6	1

33	Automated quality assessment of large digitised histology cohorts by artificial intelligence.. *Scientific Reports*, **2022**, 12, 5002	4.9	1
32	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 57	7.8	1
31	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.. *Pathobiology*, **2022**, 1-11	3.6	1
30	Reply to Rosen. *Modern Pathology*, **2017**, 30, 1505-1506	9.8	0
29	Intra-operative assessment of sentinel lymph nodes for breast cancer surgery: An update. *Surgical Oncology*, **2021**, 40, 101678	2.5	0
28	Flower lose, a cell fitness marker, predicts COVID-19 prognosis. *EMBO Molecular Medicine*, **2021**, 13, e13714	11	0
27	Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. *Breast Cancer Research and Treatment*, **2021**, 1	4.4	0
26	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. *Journal of Clinical Oncology*, **2016**, 34, 1089-1089	2.2	0
25	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. *Breast Cancer Research and Treatment*, **2021**, 188, 53-63	4.4	0
24	The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. *Molecular and Cellular Biology*, **2021**, 41, e0010321	4.8	0
23	Diagnostic concordance of phyllodes tumour of the breast. *Histopathology*, **2021**, 79, 607-618	7.3	0
22	Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study. *Histopathology*, **2021**, 79, 1087-1098	7.3	0
21	SlideGraph+: Whole Slide Image Level Graphs to Predict HER2 Status in Breast Cancer. *Medical Image Analysis*, **2022**, 102486	15.4	0
20	Brief fixation and hormone receptor expression in breast cancer. *American Journal of Surgical Pathology*, **2015**, 39, 425	6.7	
19	Molecular Classification of Breast Cancer. *Molecular Pathology Library*, **2015**, 137-155		
18	Molecular Pathology of Hormone Regulation in Breast Cancer: Hormone Receptor Evaluation and Therapeutic Implications. *Molecular Pathology Library*, **2015**, 107-118		
17	AuthorsPreply: Combining two antibodies to define E-cadherin loss of expression in non-lobular breast carcinomas: when less is more. *Histopathology*, **2013**, 63, 440-3	7.3	
16	Quantifying Lymphatic Vessel Density in Human Tissue Samples.. *Methods in Molecular Biology*, **2022**, 2441, 183-189	1.4	

15	Breast Pathology. *Encyclopedia of Pathology*, **2020**, 384-387	0
14	Predicting chemotherapy response in invasive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 1084-1084	2.1
13	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23283-e23283	2.2
12	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. *Journal of Clinical Oncology*, **2016**, 34, 1091-1091	2.2
11	Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. *Journal of Clinical Oncology*, **2016**, 34, 1092-1092	2.2
10	A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. *Journal of Clinical Oncology*, **2016**, 34, e12560-e12560	2.2
9	Metaplastic Breast Carcinomas **2017**, 153-166	
8	Histological risk factors, prognostic indicators and staging **2013**, 236-249	
7	Pathology and biology of breast cancer **2014**, 20-43	
6	Novel Immunohistochemical Based Biomarkers in Breast Cancer **2016**, 99-119	
5	The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS). *Breast Cancer Research and Treatment*, **2021**, 190, 39-51	4.4
4	L1-Regularized Neural Ranking for Risk Stratification and Its Application to Prediction of Time to Distant Metastasis in Luminal Node Negative Chemotherapy Naïve Breast Cancer Patients. *Communications in Computer and Information Science*, **2021**, 390-400	0.3
3	Applications and implications of whole-slide imaging in breast pathology. *Diagnostic Histopathology* , **2022**, 28, 149-155	0.7
2	Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. *American Journal of Cancer Research*, **2022**, 12, 469-489	4.4
1	Lessons from a breast cell annotation competition series for school pupils.. *Scientific Reports*, **2022**, 12, 7792	4.9